Organization
Cleveland Clinic Taussig Cancer Instititute
87 abstracts
Abstract
Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.Org: Cleveland Clinic Taussig Cancer Instititute,
Abstract
Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy.Org: Cleveland Clinic Taussig Cancer Instititute, Taussig Cancer Institute, Cleveland Clinic Foundation,
Abstract
Cancer burden in South Asians in the United States: Epidemiologic report using Surveillance, Epidemiology, and End Results (SEER) program.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Leukemia Program,
Abstract
Improving a polygenic risk score (PRS) for breast cancer (BC) risk assessment in diverse ancestries.Org: Myriad Genetics, Inc., Stanford University School of Medicine, Cleveland Clinic Taussig Cancer Instititute, Nashville Breast Center,
Abstract
Neoadjuvant immunotherapy for oropharynx cancer: Correlative studies and long-term outcomes from the CIAO trial.Org: Cleveland Clinic Taussig Cancer Instititute, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, City of Hope National Medical Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.Org: Berry Consultants, LLC, Seagen, Cleveland Clinic Taussig Cancer Instititute, Yale School of Medicine, University of California Irvine,
Abstract
Primary immunotherapy monotherapy (PRIMO) in locally advanced cutaneous squamous cell carcinoma.Org: Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,
Abstract
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.Org: University of Michigan Rogel Cancer Center, University of Chicago, Dana-Farber Cancer Institute, University of Wisconsin, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Results of the COMPARE-GPT study: Comparison of medication package inserts and GPT-4 cancer drug information.Org: Cleveland Clinic Taussig Cancer Instititute, Valley Health System,
Abstract
Evaluation of a web-based, interactive guide to enhance patient-clinician electronic communication.Org: Cleveland Clinic Taussig Cancer Instititute, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
Prevalence of pathogenic genetic variants in patients with gastric cancer ascertained through multi-gene panel testing.Org: University of Chicago, Invitae Corporation, The Ohio State University - James Cancer Hospital, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.Org: Huntsman Cancer Institute at the University of Utah, SWOG Statistics and Data Management Center, Seattle, WA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, University of Kentucky, Lexington, KY,
Abstract
Cardiovascular toxicity of fluoropyrimidines: Experience from a quaternary referral center.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation,
Abstract
Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms.Org: PVI, PeerView Institute for Medical Education, HealthTree Foundation, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Comprehensive assessment of adverse event profiles associated with bispecific T cell engagers in multiple myeloma.Org: 1DATA Consortium, Kansas State University–Olathe, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Plasma circulating tumor DNA in patients with cutaneous squamous cell carcinoma: Initial experience.Org: Cleveland Clinic Taussig Cancer Instititute,
Abstract
Predicting fitness for chemotherapy in older adults with metastatic bladder cancer.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Memorial Sloan Kettering Cancer Center,
Abstract
A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cleveland Clinic Taussig Cancer Instititute, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.Org: Vigeo Therapeutics, Cleveland Clinic Taussig Cancer Instititute, Boston Children’s Hospital, Vigeo Therapeutics INC,
Abstract
Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.Org: University of Michigan Medical School, Cleveland Clinic Taussig Cancer Instititute, University of Chicago, National Cancer Center East Hospital, University of Wisconsin, Madison,
Abstract
Disparities in multiple myeloma: A global perspective on drug toxicity trends.Org: DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Kansas State University–Olathe, Olathe, KS,
Abstract
Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Cleveland Clinic Brunswick Urgent Care,
Abstract
Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.Org: Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, UT Southwestern Medical Center, Medical University of South Carolina Hollings Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Stanford University School of Medicine,
Abstract
Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Cleveland Clinic Brunswick Urgent Care, Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Patient-reported usefulness of an intervention to promote job retention among women undergoing (neo)adjuvant breast cancer chemotherapy.Org: Memorial Sloan Kettering Cancer Center, Cleveland Clinic Taussig Cancer Instititute, New York City Health and Hospital Corporation/Lincoln, Montefiore Einstein Center for Cancer Care,
Abstract
Post-marketing surveillance safety analysis of patients with CNS malignancies treated with tumor treating fields (TTFields) therapy between 2011–2022.Org: Mayo Clinic Cancer Center, Thomas Jefferson University, New York-Presbyterian/Columbia University Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute,
Abstract
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.Org: Fred Hutchinson Cancer Research Center, Boston University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Medical College of Wisconsin,
Abstract
CT radiomic signature to predict overall survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma.Org: Emory University, Atlanta, GA, USA, Atlanta, GA, Cleveland Clinic Taussig Cancer Instititute, Cleveland, OH, Emory University Hospital,
Abstract
Hypersensitivity reaction to taxanes following COVID-19 vaccination.Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Txinno Bioscience, Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,
Abstract
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).Org: Vanderbilt-Ingram Cancer Center, University of Texas MD Anderson Cancer Center, University of Pennsylvania-Abramson Cancer Center, Cleveland Clinic Taussig Cancer Instititute, Massachusetts General Hospital Cancer Center and Harvard Medical School,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.Org: Cleveland Clinic Taussig Cancer Instititute, Guy’s and St Thomas’ NHS Foundation Trust, Hopital Saint-Louis, Wake Forest University School of Medicine, AOU Careggi,
Abstract
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.Org: Mayo Clinic, Rochester, MN, Jacksonville, FL, Phoenix, AZ, Wayshine Biopharm,
Abstract
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.Org: Cleveland Clinic Taussig Cancer Instititute, Beth Israel Deaconess Medical Center, Mayo Clinic, Replimune,
Abstract
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California Irvine, MD Anderson Hematology/Oncology Fellowship, The Medical College of Wisconsin,
Abstract
Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).Org: Bristol Myers Squibb, MD Anderson Cancer Center, Syapse, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States.Org: Cleveland Clinic Taussig Cancer Instititute, Huntsman Cancer Institute, University of Utah,
Abstract
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).Org: Mayo Clinic, Division of Biomedical Statistics and Informatics, Mayo Clinic Florida, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Quantitative Science Research,
Abstract
Identification of genes encoding targets associated with adverse events in multiple myeloma.Org: Kansas State University–Olathe, Taussig Cancer Center, Cleveland Clinic Taussig Cancer Instititute, University of Missouri Kansas City, Indiana University/Melvin and Bren Simon Cancer Center,
Abstract
Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications.Org: Stanford Cancer Institute, Harvard Medical School, University of California San Francisco School of Medicine, Harvard University, Tulane University School of Medicine,
Abstract
A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).Org: Memorial Sloan Kettering Cancer Center, Cleveland Clinic Taussig Cancer Instititute,
Abstract
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).Org: Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York-Presbyterian Hospital, The Tisch Cancer Institute,
Abstract
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.Org: The Institute of Cancer Research, The Royal Marsden Hospital, University of California Irvine, UPMC Hillman Cancer Center, Sarah Cannon Cancer Institute HCA Midwest Health,
Abstract
The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).Org: Sorrento Therapeutics Inc., Sorrento Therapeutics, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke Cancer Institute, Carbone Cancer Center, University of Wisconsin, Madison, WI,
Abstract
Use of machine learning derived features from CT and H&E whole-slide images to predict overall survival in head and neck squamous cell carcinoma.Org: Emory University, Atlanta, GA, USA, Therapanacea, Cleveland Clinic Taussig Cancer Instititute, Emory University Hospital, Case Western Reserve University School of Medicine,
Abstract
Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting.Org: Cleveland Clinic Taussig Cancer Instititute, Cardinal Health, Cardinal Health Specialty Solutions, Bristol Myers Squibb,
Abstract
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Western Human Nutrition Research Center, WHNRC, Davis Comprehensive Cancer Center,
Abstract
Adherence to surveillance guidelines in survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study (CCSS).Org: Cleveland Clinic Taussig Cancer Instititute, University of Alberta, St. Jude Children's Research Hospital, Fred Hutchinson Cancer Research Center, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lombardi Comprehensive Cancer Center, University of Berne and Cantonal Hospital of Lucerne,
Abstract
The role of private insurance characteristics in the out-of-pocket costs of patients with multiple myeloma.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland, OH,
Abstract
The impact of patient age on palliative care utilization and end-of-life outcomes among metastatic breast cancer patients.Org: University Hospitals Sussex NHS Foundation Trust, Department of Medicine, Icahn School of Medicine at Mount Sinai, Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology, Case Western Reserve University School of Medicine,
Abstract
Longitudinal trends in serum calcium, parathormone and bone mineral density in breast cancer survivors on aromatase inhibitor therapy: A single institutional cohort study.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, University of Pittsburgh Medical Center, Endocrinology and metabolic institute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Demographic disparities in lung cancer mortality and trends in the United States between 1999 and 2020: A population-based CDC database analysis.Org: The University of Toledo College of Medicine and Life Sciences, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation,
Abstract
Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.Org: Huntsman Cancer Institute at the University of Utah, University of Utah/Huntsman Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, SWOG Statistics and Data Management Center, Seattle, WA, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Neutrophil-to-lymphocyte ratio as a predictor of immune checkpoint inhibitor therapy response in advanced bladder cancer.Org: Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Taussig Cancer Instititute, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Immune-related hypophysitis: An analysis of a heterogeneous entity.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Faith-based communities’ preferred interventions to improve the participation of black/African-American persons in medical research and clinical trials: A focus group study.Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Main Campus,
Abstract
Overall survival trends of papillary thyroid cancer: A Surveillance, Epidemiology, and End Results (SEER) population-based data (2002-2016).Org: MetroHealth System/Case Western Reserse University, Seidman Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Instititute, St. Vincent's Medical Center, Bridgeport, CT,
Abstract
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).Org: Roswell Park Comprehensive Cancer Center, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Saint Vincent Hospital Cancer Center Green Bay,
Abstract
Patterns and outcomes of palliative radiation therapy with immunotherapy in locally recurrent head and neck squamous cell carcinoma.Org: Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Cleveland Clinic Brunswick Urgent Care,
Abstract
Acute lymphocytic leukemia incidence and survivability trends in the United States over the last two decades: SEER data set from 2000-2019.Org: Huntington Beach High School, Leukemia Program, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Impact of COVID-19 pandemic on lung cancer diagnosis in a community hospital.Org: Saint Vincent Hospital Cancer Center Green Bay, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.Org: National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Cleveland Clinic Taussig Cancer Instititute, Medical College of Wisconsin, NYU Langone Laura and Isaac Perlmutter Cancer Center,
Abstract
A novel risk assessment metric for antimyeloma therapies and drug interactions.Org: Kansas State University–Olathe, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Myeloma Program,
Abstract
Prospective evaluation of cell-free DNA fragmentation profiles for lung cancer detection.Org: NYU Langone Health, New York, NY, Cleveland Clinic Taussig Cancer Instititute, University of Pennsylvania, Delfi Diagnostics, Inc., The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, Fred Hutchinson Cancer Center, Seattle, WA, Virginia Oncology Associates, Hampton, VA, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, Allegheny Health Network Cancer Institute, Pittsburgh, PA, University of California San Diego, La Jolla, CA, Dana-Farber Cancer Institute, Boston, MA, Indiana University Health Arnett Cancer Center, Lafayette, IN, University at Buffalo, Buffalo, NY, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Oregon Health and Science University Knight Cancer Institute, Portland, OR, University of Chicago, Chicago, IL,
Abstract
Differentiating bladder cancer (BLCA) tumor immune microenvironment (TME) profiles based on predicted intrinsic radiosensitivity (RS).Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute, Exact Sciences Corporation, GenomOncology, University of Michigan,
Abstract
A population-level analysis of survival in patients with ALK+ anaplastic large cell lymphoma (ALCL) in the era of novel therapies.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Department of Translational Hematology and Oncology Research, Lerner Research Institute, Lerner Research Institute,
Abstract
AI-based pathologic biomarker for pathologic downstaging in patients with muscle-invasive bladder cancer undergoing cystectomy after neoadjuvant nivolumab, gemcitabine, and cisplatin: BLAAST-1 Trial.Org: Valar Labs, Inc., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Huntsman Cancer Institute, Hunstman Cancer Institute at the University of Utah,
Abstract
Mechanisms of sensitivity to platinum-based chemotherapy in PD-1 blockade-refractory head and neck cancer.Org: Case Western Reserve School of Medicine, Cleveland, OH, Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,
Abstract
Real world outcome of neuroendocrine carcinomas of the bladder compared to conventional tumors of the bladder.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Glickman Urological and Kidney Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Cleveland Clinic/Fairview Hospital,
Abstract
A pilot study to determine the effects of early palliative care integration on patients with newly diagnosed multiple myeloma.Org: Cleveland Clinic Taussig Cancer Instititute, Taussig Cancer Institute,
Abstract
Association of surgery and radiotherapy with risk of thoracic soft tissue sarcoma among older survivors of breast cancer.Org: National Institutes of Health All of Us Research Program, Bethesda, VA, MD Anderson Cancer Center, National Cancer Institute, Vilnius, Lithuania, NCI/NIH,
Abstract
Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC).Org: Cleveland Clinic Lerner College of Medicine, John D. Dingell VA Hospital, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Lerner Research Institute, Cleveland, OH,
Abstract
The efficacy of autologous hematopoietic cell transplantation in standard risk multiple myeloma refractory to multiple therapies.Org: Department of Translational Hematology and Oncology Research, Lerner Research Institute, Lerner Research Institute, Cleveland Clinic Taussig Cancer Instititute, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, OH, Cleveland Clinic Taussig Cancer Center, Cleveland, OH,
Abstract
Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).Org: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Cleveland Clinic Taussig Cancer Instititute, Gabrail Cancer Center, Roswell Park Cancer Institute, Boca Raton Regional Hospital, Lynn Cancer Institute,
Abstract
Impact of BAP1 mutational status on immunotherapy outcomes in advanced malignant pleural mesothelioma: A single institution experience.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Relationship between androgen biosynthesis linked to 3βHSD1 and resistance to radiotherapy: A germline biomarker for combined androgen blockade with radiation in high-risk prostate cancer.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Lerner College of Medicine,
Abstract
The association of demographic factors and disease stage on palliative care (PC) referral rates and completion of advanced directives in a lung cancer (LC) patient population.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals, Indiana University School of Medicine Department of Medicine, IU Hematology/Oncology,
Abstract
Association of weight loss with risk of myelodysplastic syndromes (MDS) in adults with obesity: Insights from the SPLENDID cohort.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Cleveland, OH, Bariatric and Metabolic Institute,
Abstract
Health care provider and hospital decision-maker perceptions and beliefs on global environmental sustainability in the operating room.Org: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Digestive Disease Institute, Cleveland Clinic Taussig Cancer Instititute, Cleveland, OH, Trinity Life Sciences,
Abstract
Incidence of skin cancer among patients with Waldenström macroglobulinemia: Analysis of the SEER database (2000-2019).Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, Cleveland Clinic Taussig Cancer Instititute, Cleveland, OH, Saint Vincent Hospital Cancer Center Green Bay,
Abstract
ANTIBODY RESPONSE TO PNEUMOCOCCAL AND INFLUENZA VACCINATION IN PATIENTS WITH RA RECEIVING SUBCUTANEOUS ABATACEPT Org: Bristol-Myers Squibb, Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, United States of America, Cleveland Clinic Taussig Cancer Instititute, University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, Johns Hopkins University, Division of Rheumatology, Department of Medicine, Baltimore, MD, United States of America,
Abstract
ASSOCIATION OF PROTEINASE 3 GENE (PRTN3) Val119Ile POLYMORPHISM (SNP rs351111) WITH RISK OF RELAPSE AMONG HOMOZYGOUS PATIENTS WITH PR3 ANCA-ASSOCIATED VASCULITISOrg: Mayo Clinic, National Intitute of Health, Genentech Inc., University of Groningen, Cleveland Clinic Taussig Cancer Instititute,